

# Different types of atrophy in the prostate with and without adenocarcinoma

---

**Tomas, Davor; Krušlin, Božo; Rogatsch, Hermann; Schäfer, Georg; Belicza, Mladen; Mikuz, Gregor**

*Source / Izvornik:* **European Urology, 2007, 51, 98 - 104**

**Journal article, Accepted version**

**Rad u časopisu, Završna verzija rukopisa prihvaćena za objavljivanje (postprint)**

<https://doi.org/10.1016/j.eururo.2006.06.001>

*Permanent link / Trajna poveznica:* <https://urn.nsk.hr/urn:nbn:hr:105:380146>

*Rights / Prava:* [In copyright](#) / [Zaštićeno autorskim pravom.](#)

*Download date / Datum preuzimanja:* **2025-04-01**



*Repository / Repozitorij:*

[Dr Med - University of Zagreb School of Medicine  
Digital Repository](#)





### **Središnja medicinska knjižnica**

Tomas, D., Krušlin, B., Rogatsch, H., Schäfer, G., Belicza, M., Mikuz, G. (2007)  
*Different Types of Atrophy in the Prostate With and Without Adenocarcinoma.*  
European Urology, 51 (1). pp. 98-104.

<http://www.sciencedirect.com/science/journal/03022838>

<http://medlib.mef.hr/149/>

University of Zagreb Medical School Repository

<http://medlib.mef.hr/>

1 DIFFERENT TYPES OF ATROPHY IN PROSTATE WITH AND WITHOUT  
2 ADENOCARCINOMA

3 Davor Tomas, Božo Krušlin, <sup>1</sup>Hermann Rogatsch, <sup>1</sup>Georg Schäfer,  
4 Mladen Belicza, <sup>1</sup>Gregor Mikuz

5 Ljudevit Jurak Department of Pathology, Sestre milosrdnice University Hospital, Zagreb,  
6 Croatia

7 <sup>1</sup>Institute of Pathology, Medical University Innsbruck, Innsbruck, Austria

8

9 **Corresponding author:**

10 Davor Tomas, MD, PhD

11 Ljudevit Jurak Department of Pathology, Sestre milosrdnice University Hospital,  
12 Vinogradska 29, 10000 Zagreb

13 Tel: +385 1 3787 909, Fax: +385 1 3787 244, E-mail: [dtomas@kbsm.hr](mailto:dtomas@kbsm.hr)

14

15 **Word count:** 2483 words

16 **Key words:** Proliferative atrophy; Proliferative inflammatory atrophy; Prostate  
17 adenocarcinoma

18 **“Take-home message” of the article:** Different types of atrophy may be found in prostate  
19 with and without carcinoma. We showed that proliferative inflammatory atrophy (PIA) was  
20 significantly associated with carcinoma thus suggesting that PIA might play role in  
21 development of prostatic carcinoma.

22

**1 ABSTRACT**

2 **OBJECTIVE:** The purpose of this study is to evaluate the extent and type of atrophy  
3 lesions, according to classification proposed by Working group in radical prostatectomy  
4 specimens obtained from patients with prostatic carcinoma and benign prostatic hyperplasia  
5 (BPH) and compare prevalence and types of atrophy between two investigated groups.

6 **METHODS:** The total of 1096 slides from 50 patients with carcinoma and 277 slides from  
7 31 patients with BPH were histologically analyzed to evaluate the number of foci and type  
8 of atrophic lesions according to the new prostatic atrophy classification.

9 **RESULTS:** Age, Gleason grade and TNM showed no significant correlation with the  
10 number of proliferative atrophy (PA) and proliferative inflammatory atrophy (PIA) foci  
11 ( $p>0.05$ ). PIA was significantly more frequent in prostate with carcinoma (1.63 versus 1.27  
12 atrophic lesions per slide) ( $p<0.001$ ) while PA displayed an increased frequency in BPH  
13 (2.28 versus 0.76 atrophic lesions per slide) ( $p<0.001$ ).

14 **CONCLUSION:** We confirmed that PA and PIA are common findings in prostate with and  
15 without carcinoma, but the question whether the inflammation produces tissue damage and  
16 proliferative atrophy or some other insult induces the tissue damage and atrophy directly,  
17 with inflammation occurring secondarily, is still unresolved.

## 1 1. INTRODUCTION

2           Approximately 20% to 30% of the world's cancer burden can be traced to infectious  
3 agents thought to act through the production of chronic infections and subsequent chronic  
4 inflammation [1-3]. In the prostate factors that determine the risk of developing clinical  
5 carcinoma are not well known; however it was clearly showed that chronic inflammation is  
6 associated with both postatrophic hyperplasia and focal simple atrophy [4,5]. The term  
7 proliferative inflammatory atrophy (PIA) was proposed to designate discrete foci of  
8 proliferative glandular epithelium with the morphologic appearance of simple atrophy or  
9 postatrophic hyperplasia occurring in association with inflammation. De Marzo et al. and  
10 Putzi and De Marzo suggested that PIA could be a precursor to prostatic adenocarcinoma  
11 directly, or may lead to carcinoma indirectly via development into high grade prostatic  
12 intraepithelial neoplasia (HGPIN) [5-9]. This finding supports a model whereby the  
13 proliferative epithelium in PIA may progress to HGPIN and subsequently to prostatic  
14 adenocarcinoma [8]. Investigations of frequency, distribution, proliferative state, molecular  
15 changes, and chromosome 8 gain in PIA also suggested connection between PIA, HGPIN  
16 and prostatic carcinoma [10-14]. This hypothesis is questioned by other authors, and its role  
17 as a precursor lesion has been controversial [15-21].

18           Recently, Working group for histological classification of prostate atrophy lesions  
19 proposed classification of focal prostate epithelial atrophy lesions in the two main groups.  
20 The major distinction between proposed groups was content of inflammatory cells. Focal  
21 atrophy lesions that contain an increase in inflammation above that found in normal tissue  
22 were classified as PIA and those without inflammation were considered as a proliferative  
23 atrophy (PA). Each group, whether it is considered PIA or PA was sub-classified into the  
24 following types: simple atrophy, simple atrophy with cyst formation, post-atrophic

1 hyperplasia, partial atrophy and mixed lesions. Working group also noted that vast majority  
2 of focal atrophy lesions contained at least some inflammation that was beyond that found in  
3 normal epithelium and, therefore, most atrophy lesions were considered PIA [22].

4         The purpose of this study is to evaluate the extent and type of atrophy lesions  
5 according to classification proposed by Working group, in radical prostatectomy specimens  
6 obtained from patients with prostatic carcinoma and benign prostatic hyperplasia (BPH)  
7 and compare prevalence and types of atrophy between two investigated groups.

## 1 2. MATERIAL AND METHODS

2 Our study group included randomly chosen radical prostatectomy specimens of 50  
3 patients with prostatic adenocarcinoma diagnosed at the Department of Pathology, Leopold  
4 Franzens University Hospital Innsbruck, and simple open prostatectomy specimens of 31  
5 patients with benign prostatic hyperplasia (BPH) diagnosed at the Ljudevit Jurak  
6 Department of Pathology, Sestre milosrdnice University Hospital Zagreb. At the time of  
7 diagnosis all patients were clinically without lymph node or distant metastases and patients  
8 were not previously treated for prostatic cancer or other primary tumour.  
9 Lymphadenectomy was performed in 13 patients.

10 The age range of the patients with carcinoma was between 43 and 79 years (median  
11 age 60.4), and age range of the patients with BPH was between 56 and 86 years (median  
12 age 69.7).

13 Specimens were fixed in 10% buffered formalin, embedded in paraffin, cut at 5 µm  
14 thickness, and routinely stained with hematoxylin and eosin. The diagnosis of  
15 adenocarcinoma and BPH was histologically confirmed in all cases. We evaluated each  
16 case as a whole, without regard to separate parts. Cases with carcinoma consisted from 16  
17 to 42 slides, and cases with BPH consisted from 6 to 22 slides. All 1096 slides with  
18 carcinoma and 277 slides with BPH were microscopically sistematically analyzed to  
19 evaluate number of foci and type of atrophic lesions according the new atrophy  
20 classification proposed by Working group for histological classification of prostate atrophy  
21 lesions in two main types [22]. Following five subtypes are recognized. Simple atrophy is  
22 characterized by acini with relatively normal caliber that lack papillary fronds and were  
23 lined with atrophic cells. Simple atrophy with cyst formation is similar to simple atrophy  
24 but with some rounded and cyst-like glands. Post-atrophic hyperplasia is characterized with

1 smaller and round acini which appear in lobular distribution and often surrounding a  
2 somewhat dilated duct. In partial atrophy luminal cells contain less cytoplasm than normal,  
3 which is mostly clear. The architectural arrangement of glands can be similar to that of  
4 either simple atrophy or post-atrophic hyperplasia. Mixed atrophy contains admixed two or  
5 more above mentioned types [22]. Only atrophic lesions that contain an increase in  
6 inflammation above that found in adjacent tissue with normal appearing glands were  
7 classified as proliferative inflammatory atrophy. Atrophic lesions without inflammation or  
8 with inflammation which was sparse compared to adjacent tissue with normal appearing  
9 glands were considered as proliferative atrophy. Whole slides were screened under low  
10 magnification and type and quantity of inflammation were determined under high power  
11 field (400X). In cases of confluent areas of atrophy, foci were counted as separated only  
12 when intervening normal appearing glands or fibromuscular stroma without glands clearly  
13 made distinction between them.

14 The differences in the appearance, extent and type of atrophy lesions between  
15 carcinoma and BPH were tested using Spearman rank order correlation test, Mann-Whitney  
16 U test, Wilcoxon matched pairs test and  $\chi^2$  test. For all analyses type error of 5% was  
17 considered statistically significant ( $p < 0.05$ ).



### 1 3. RESULTS

2 Patients with benign prostatic hyperplasia (BPH) were significantly older compared  
3 to patients with prostatic adenocarcinoma ( $p<0.05$ ). Statistical analysis revealed no  
4 significant correlation between age and appearance of proliferative atrophy (PA) and  
5 proliferative inflammatory atrophy (PIA) in cases with carcinoma and BPH ( $p>0.05$ ).

6 The Gleason score and pTNM distribution are shown in Table 1 and 2. Eighteen  
7 tumors (36.0%) were moderately differentiated (Gleason score 5 and 6) and 32 (64.0%)  
8 were poorly differentiated (Gleason score 7 to 9). The most common Gleason grade was 3.  
9 In 45 (90.0%) tumors, one or both grades were three. Thirty-four tumors (68.0%) were  
10 confined to prostate and 16 (32.0%) were spread through prostatic capsule. Gleason grade  
11 and TNM showed no significant correlation with number of PA and PIA foci ( $p>0.05$ ).

12 In all 81 prostates (50 with carcinoma and 31 with BPH) foci with PA and PIA were  
13 found. Proliferative atrophy in BPH was significantly more frequent compared to PIA (2.28  
14 versus 1.27 focuses per slide) ( $p<0.001$ ), whereas in cases with carcinoma PIA significantly  
15 outnumbered PA (1.63 versus 0.76 focuses per slide) ( $p<0.001$ ) (Table 3).

16 The most common type of PA in slides with carcinoma and BPH was type 2 or  
17 simple atrophy with cyst formation, and 0.45 and 1.67 focus per slide of this atrophy type  
18 was found, respectively (Fig. 1A). Out of total number of PA in BPH and carcinoma, 461  
19 (72.9%) and 489 (58.9%) were PA type 2 (Table 3).

20 Statistical analysis revealed that cases with BPH showed significantly higher  
21 frequency of PA than cases with carcinoma (2.28 versus 0.76 atrophic lesions per slide)  
22 ( $p<0.001$ ).

23 On the contrary, PIA was significantly more frequent in prostate with carcinoma  
24 (1.63 versus 1.27 atrophic lesions per slide) ( $p<0.05$ ). Increased PIA in prostate cancer in

1 comparison to BPH is mostly driven by type 1 ( $p<0.001$ ) and type 5 ( $p<0.001$ ) atrophic  
2 lesions (Table 3).

3         The most common type of PIA in both analyzed groups was type 1 (simple atrophy)  
4 (Fig. 1B). In slides with carcinoma 616 (34.4%) or 0.56 foci per slides of type 1 atrophy  
5 were found. The second most frequent type was mixed lesions (type 5) with 394 (22.0%) or  
6 0.36 foci per slide. In BPH proliferative inflammatory atrophy type 1 was noted in 90  
7 (25.5%) or 0.33 foci per slide. Slightly less common types of PIA in BPH were type 2 and  
8 3 (0.31 and 0.32 foci per slide, respectively) (Table 3).

9         PA and PIA were most commonly observed in peripheral zone of prostate.  
10 Inflammatory infiltrate around atrophic glands in cases of PIA mainly consisted of  
11 lymphocytes with varying numbers of macrophages.

#### 1 4. DISCUSSION

2 Chronic inflammation has been implicated in the development of tumors in wide  
3 range of organs including liver, stomach, pancreas and, urinary bladder [1-3]. Recent  
4 investigations also suggested connection between inflammation and prostatic carcinoma.  
5 Focal atrophy, which is often associated with chronic, and less frequently, acute  
6 inflammation has been especially suspicious [5-10]. De Marzo et al. proposed the term  
7 proliferative inflammatory atrophy (PIA) for this type of atrophy, and suggested its  
8 implication in prostatic carcinogenesis [5]. Unlike the type of prostatic atrophy associated  
9 with androgen depletion (hormonal atrophy), epithelial cells in PIA have low frequency of  
10 apoptosis, high proliferative index and share some molecular and genetics markers with  
11 prostatic carcinoma [11-14].

12 However, this hypothesis is not confirmed by some others, mostly morphological  
13 and epidemiological investigations, which found no connection between PIA and prostatic  
14 carcinoma [15-21].

15 In an autopsy study on 100 serially sectioned peripheral zone of the prostates from  
16 men older than 40 years, Billis found atrophic lesions in 85 of the 100 examined prostates,  
17 but did not confirm significant connection between the prevalence of atrophy and high  
18 grade prostatic intraepithelial neoplasia (HGPIN) or prostatic carcinoma [15].

19 Billis and Magna also denied the role of atrophy in prostatic carcinogenesis and  
20 suggested possible role of ischemia in etiopathogenesis of prostatic atrophy [16]. Same  
21 authors investigated inflammatory atrophy in an autopsy study and observed inflammatory  
22 atrophy in 66% and atrophy without inflammation in 22% of analyzed cases. The authors  
23 found no association between the presence of inflammatory atrophy and the likelihood of  
24 cancer and no topographic association between atrophy and prostate cancer foci and

1 concluded that possible cause of inflammatory infiltrate associated with prostatic atrophy  
2 might be due to extravasated prostatic secretion, which was commonly noted in areas of  
3 eroded epithelium [17].

4 Bakshi et al. studied 79 consecutive prostate biopsies: 54% of initial biopsies were  
5 benign, 42% of the cases showed cancer, and 4% HGPIN or atypia. Postatrophic  
6 hyperplasia (PAH) was seen in 17% of benign initial biopsies with available follow-up. Of  
7 these, 75% had associated inflammation. There was no significant difference in the  
8 subsequent diagnosis of prostate cancer for groups with postatrophic hyperplasia, partial  
9 atrophy, atrophy, or no specific abnormality. The authors concluded that the subcategories  
10 of atrophy do not appear to be associated with a significant increase in the risk of diagnosis  
11 of prostate cancer subsequently [18].

12 Similar findings were reported by Postma et al. in their investigation about  
13 connection of appearance and extent of atrophy in sextant needle biopsy and subsequent  
14 risk for development of prostatic carcinoma [19]. They observed atrophy lesions in 94% of  
15 analyzed cases but patients with extensive atrophy were not exposed to increased risk for  
16 development of HGPIN or carcinoma [19].

17 In our investigation, atrophy was found in all analyzed prostatectomy specimens  
18 with and without carcinoma. De Marzo et al. found that 55 foci of atrophy in specimens  
19 consisted of portion of tissue dissected immediately after radical prostatectomy from 42  
20 patients [5]. Similar frequency of atrophy is reported in two investigations of Billis (85%  
21 and 88%) and Postma (94%), who analyzed peripheral zone of prostate from autopsied men  
22 and sextant core needle biopsy from patients without diagnosed carcinoma [15,17,19].

23 Our patients with benign prostatic hyperplasia (BPH) were significantly older than  
24 patients with carcinoma, but age was not found as relevant factor, which could influence

1 the appearance of proliferative atrophy (PA) and PIA in cases with BPH and carcinoma. On  
2 the contrary, Billis and Di Silverio et al. reported increased number of atrophic foci in aged  
3 patients [15,20]. We also found that Gleason score and TNM were not correlated with the  
4 number of PA and PIA foci in cases with carcinoma.

5 The most common type of PA was type 2, and the most common type of PIA was  
6 simple atrophy (type 1) in both analyzed groups. In investigation of De Marzo et al. the  
7 most frequently observed atrophy types were simple atrophy and simple atrophy with cyst  
8 formation [5]. Postma et al. also recently reported that simple atrophy is very common  
9 lesion in a sextant needle core biopsy from population without carcinoma [19].

10 We found that postatrophic hyperplasia (type 3), which is histologically most  
11 commonly confused with prostatic carcinoma, was almost equally distributed in cases with  
12 and without carcinoma. Approximately one focus of this atrophy type was usually found in  
13 every third slide in both analyzed cases.

14 Anton et al. analyzed the presence, location and the number of foci of postatrophic  
15 hyperplasia. They found postatrophic hyperplasia in 32% of radical prostatectomy  
16 specimens and in 12% of cystoprostatectomy specimens and concluded that postatrophic  
17 hyperplasia is relatively common lesion but without any association with prostatic  
18 carcinoma [21].

19 In our study, PA was more frequent in benign cases compared to PIA and these  
20 patients had also significantly higher number of PA foci compared to patients with  
21 carcinoma. On the other hand, in patients with carcinoma PIA was more prevalent  
22 compared to PA and slides from these patients contained significantly higher number of  
23 PIA focuses compared to slides with BPH. However, slides with carcinoma contained  
24 peripheral and transitional zone while slides with BPH were mainly composed of

1 transitional zone. Thus obtained different prevalence of atrophy in malignant and benign  
2 cases could partially reflect the difference in distribution between various anatomic  
3 compartments of the prostate.

4 To our knowledge only two studies compared the appearance and frequency of  
5 inflammatory and non-inflammatory atrophy in patients with and without carcinoma. In  
6 these studies, no significant differences were found between the presence and types of  
7 atrophy in patients containing carcinoma with controls without carcinoma [15,17].

## 1 **5. CONCLUSION**

2           In conclusion, we confirmed that proliferative atrophy (PA) and proliferative  
3 inflammatory atrophy (PIA) are common findings in prostate with and without carcinoma,  
4 especially in the peripheral zone of prostate. Age, Gleason grade and TNM showed no  
5 significant connection with number of PA and PIA foci. PIA outnumbered PA in cases with  
6 carcinoma compared to benign prostatic hyperplasia (BPH), but the question whether the  
7 inflammation produce tissue damage and proliferative atrophy or some other insult induces  
8 the tissue damage and atrophy directly, with inflammation occurring secondarily, is still  
9 unresolved.

## 1 6. REFERENCES

- 2 1. Weitzman SA, Gordon LI. Inflammation and cancer: role of phagocyte-generated  
3 oxidants in carcinogenesis. *Blood* 1990;76:655–63.
- 4 2. Farrow B, Evers BM. Inflammation and the development of pancreatic cancer. *Surg*  
5 *Oncol* 2002;10:153-69.
- 6 3. Ohshima S, Tatemichi M, Sawa T. Chemical basis of inflammation-induced  
7 carcinogenesis. *Arch Biochem Biophys* 2003;417:3-11.
- 8 4. Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. *Eur Urol*  
9 2005;48:546-51.
- 10 5. De Marzo AM, Marchi VL, Epstein JI, et al. Proliferative inflammatory atrophy of  
11 the prostate: implications for prostatic carcinogenesis. *Am J Pathol* 1999;155:1985–  
12 92.
- 13 6. Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. *J Urol*  
14 2004;171:S36-40.
- 15 7. Palapattu GS, Sutcliffe S, Bastian PJ, et al. Prostate carcinogenesis and  
16 inflammation: emerging insights. *Carcinogenesis* 2005;26:1170-81.
- 17 8. Putzi MJ, De Marzo AM. Morphological transitions between proliferative  
18 inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. *Urology*  
19 2000;56:828–32.
- 20 9. De Marzo AM, Meeker AK, Zha S, et al. Human prostate cancer precursor and  
21 pathobiology. *Urology* 2003;62:55-62.
- 22 10. Shah R, Mucci NR, Amin A, Macoska JA, Rubin MA. Postatrophic hyperplasia of  
23 the prostate gland: neoplastic precursor or innocent bystander? *Am J Pathol*  
24 2001;158:1767-73.



- 1 11. Tsujimoto Y, Takayama H, Nonomura N, Okuyama A, Aozasa K. Postatrophic  
2 hyperplasia of the prostate in Japan: histologic and immunohistochemical features  
3 and p53 gene mutation analysis. *Prostate* 2002;52:279-87.
- 4 12. Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate  
5 hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and  
6 cell proliferation in the glandular epithelium. *Prostate* 2004;61:60-72.
- 7 13. Fatih D, Han S, Lee DK, et al. P16 is upregulated in proliferative inflammatory  
8 atrophy of the prostate. *Prostate* 2005;65:73-82.
- 9 14. Uetsuki H, Tsunemori H, Taoka R, Haba R, Ishikawa M, Kakehi Y. Expression of a  
10 novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the  
11 prostate. *J Urol* 2005;174:514-8.
- 12 15. Billis A. Prostatic atrophy. An autopsy study of a histologic mimic of  
13 adenocarcinoma. *Mod Pathol* 1998;11:47-54.
- 14 16. Billis A, Magna LA. Prostate elastosis: a microscopic feature useful for the  
15 diagnosis of postatrophic hyperplasia. *Arch Pathol Lab Med* 2000;124:1306-9.
- 16 17. Billis A, Magna LA. Inflammatory atrophy of the prostate. Prevalence and  
17 significance. *Arch Pathol Lab Med* 2003;127:840-4.
- 18 18. Bakshi NA, Pandya MW, Schervish EW, Wojno KJ. Morphologic features and  
19 clinical significance of postatrophic hyperplasia in biopsy specimens of prostate.  
20 *Mod Pathol* 2002;15:154A.
- 21 19. Postma R, Schroder FH, van der Kwast TH. Atrophy in prostate needle biopsy cores  
22 and its relationship to prostate cancer incidence in screened men. *Urology*  
23 2005;65:745-9.

- 1 20. Di Silverio F, Gentile V, De Matteis A, et al. Distribution of inflammation, pre-  
2 malignant lesions, incidental carcinoma in histologically confirmed benign prostatic  
3 hyperplasia: a retrospective analysis. *Eur Urol* 2003;43:164-75.
- 4 21. Anton RC, Kattan MW, Chakraborty S, Wheeler TM. Postatrophic hyperplasia of  
5 the prostate: lack of association with prostate cancer. *Am J Surg Pathol*  
6 1999;23:932-6.
- 7 22. De Marzo AM, Platz EA, Epstein JI et al. A Working group classification of focal  
8 prostate atrophy lesions. *Am J Surg Pathol* 2006 (In press)

1 Table 1. Distribution of Gleason grades and scores in 50 patients with prostatic  
2 adenocarcinoma.

3

Gleason grades with scores	Number of cases	%
5 (2+3)	3	6.0
5 (3+2)	4	8.0
6 (3+3)	11	22.0
7 (3+4)	20	40.0
7 (4+3)	3	6.0
8 (3+5)	3	6.0
8 (4+4)	3	6.0
8 (5+3)	1	2.0
9 (4+5)	2	4.0
Total	50	100

4

1 Table 2. Distribution of pTNM in 50 patients with prostatic adenocarcinoma.

2

3

pTNM	Number of cases	%
T2aNxMxR0	1	2.0
T2aNxMxR1	1	2.0
T2aN0MxR1	1	2.0
T2bNxMxR1	1	2.0
T2bN0MxR0	5	10.0
T2cNxMxR0	19	38.0
T2cNxMxR1	6	12.0
T3aNxMxR0	3	6.0
T3aNxMxR1	5	10.0
T3aN0MxR0	3	6.0
T3aN0MxR1	1	2.0
T3bNxMxR1	1	2.0
T3bN0MxR1	3	6.0
Total	50	100

4

1 Table 3. The number and type of atrophy lesions in 1096 slides of 50 patients with prostatic  
 2 adenocarcinoma and in 277 slides of 31 patients with benign prostatic hyperplasia

3

	Prostatic adenocarcinoma (n=1096)				Benign prostatic hyperplasia (n=277)			
	PA*		PIA**		PA*		PIA**	
	Number (%)	Number per slide	Number (%)	Number per slide	Number (%)	Number per slide	Number (%)	Number per slide
Type 1	117 (14.1%)	0.11	616 (34.4%)	0.56	70 (11.1%)	0.25	90 (25.5%)	0.33
<sup>§</sup> Type 2	489 (58.9%)	0.45	339 (18.9%)	0.31	461 (72.9%)	1.67	86 (24.4%)	0.31
Type 3	37 (4.5%)	0.03	332 (18.5%)	0.30	6 (0.9%)	0.02	88 (24.9%)	0.32
<sup>§</sup> Type 4	58 (7.0%)	0.05	110 (6.2%)	0.10	22 (3.5%)	0.08	24 (6.8%)	0.09
Type 5	129 (15.5%)	0.12	394 (22.0%)	0.36	73 (11.6%)	0.26	65 (18.4%)	0.22
Total	830 (100%)	0.76	1791 (100%)	1.63	632 (100%)	2.28	353	1.27

4

5 \*PA – proliferative atrophy; \*\*PIA – proliferative inflammatory atrophy

1 §type 2 and §type 4 atrophy are not yet formally considered proliferative inflammatory  
2 atrophy or proliferative atrophy since studies of these lesion looking at proliferation have  
3 not been published [22]

4

5 Legend:


6 Type 1 – simple atrophy

7 Type 2 – simple atrophy with cyst formation

8 Type 3 – post-atrophic hyperplasia

9 Type 4 – partial atrophy

10 Type 5 – mixed lesions



1

2 A

B

3 Figure 1. The most common type of proliferative atrophy in slides with benign prostatic  
4 hyperplasia and prostatic adenocarcinoma was simple atrophy with cyst formation (A),  
5 while simple atrophy was most frequent type of proliferative inflammatory atrophy in both  
6 analyzed groups (B). (Both microphotographs made under magnification of 200x.)